Chinese Hepatolgy ›› 2022, Vol. 27 ›› Issue (12): 1292-1295.

• Liver Cancer • Previous Articles     Next Articles

The efficacy and safety of DEB-TACE compared with cTACE in the treatment of unresectable intrahepatic cholangiocarcinoma

HE Hai-tao1, LIU Shang-da2, WEI Guang-xu3, XU Kang-xiang2, ZHOU Peng-cheng2   

  1. 1. Department of Radiology, Huai-an Medical District of Eastern Theater General Hospital, Jiangsu 223001, China;
    2. Department of Radiology, Huai’an No.82 Hospital, Jiangsu 223001, China;
    3. Department of Intervention, First Affiliated Hospital of Navy Military Medical University, Shanghai 200433, China
  • Received:2022-02-08 Published:2023-01-30
  • Contact: HE Hai-tao,Email:pla82hht@126.com

PDF (PC)

164

Abstract: Objective To compare the efficacy and safety of transarterial chemoembolization using drug-eluting bead transarterial chemoembolization (DEB-TACE) and traditional transarterial chemoembolization (cTACE) in the treatment of unresectable intrahepatic cholangiocarcinoma (ICC).Methods From May 1, 2016 to May 1, 2021, thirty five patients with ICC in our hospital were retrospectively analyzed. Among them, 17 patients received DEB-TACE and 18 patients received cTACE. After 4 to 8 weeks, the patients were evaluated according to the solid tumor efficacy evaluation criteria (RECIST) and followed up for survival, and the efficacy of the treatments in two groups was compared. The postoperative adverse events were recorded and compared between the two treatment groups. The degree of pain was evaluated by visual analogue scale (VAS). The degree of vomiting and fever was evaluated according to CTCAE version 4.0 and the liver function of patients before and 3 days after operation was compared.Results The overall Objective response rate (ORR) of patients in the DEB-TACE group was significantly higher than that in the cTACE group (58.8% vs. 16.7%, P=0.012). The median survival period of patients in the DEB-TACE group was 14 (9, 24) months, which was longer that in the cTACE group 12 (8, 24) months (P=0.697). There were no severe adverse events in the two groups after operation, but the incidence of post-embolization syndrome in the DEB-TACE group was significantly higher than that in the cTACE group (94.1% vs. 55.6%, P=0.026), and abdominal pain was the most common symptom (94.1% vs. 44.4%, P=0.002). However, different degrees of liver function injury occurred in both groups after surgery, and the difference was not statistically significant (P>0.05).Conclusion DEB-TACE is safe and effective in the treatment of unresectable ICC without distant metastasis, and its short-term efficacy for unresectable ICC is better than that of cTACE.

Key words: Transarterial chemoembolization, Drug-eluting beads, Intrahepatic cholangiocarcinoma, Safety, Effective